MetaCap

Processa Pharmaceuticals Inc. Company Profile

NASDAQ: PCSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.56-0.13 (-7.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Processa Pharmaceuticals at a glance

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Vero Beach, FL. Processa Pharmaceuticals is led by Mr. George K. Ng Esq., J.D. and employs about 12 people. At a market capitalization of $4.4 million, it is considered a small-cap company.

Its SEC Central Index Key (CIK) is 0001533743, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Processa Pharmaceuticals do?

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.

Business description based on the company's public filings.

Company information

Legal name
Processa Pharmaceuticals Inc.
Ticker
NASDAQ: PCSA
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. George K. Ng Esq., J.D.
Employees
12
Headquarters
601 21st Street, Vero Beach, FL, United States
Phone
772 453 2899
SEC CIK
0001533743
Latest annual report
10-K/A · Apr 30, 2026

Companies similar to Processa Pharmaceuticals

PCSA peer companies
CompanyPrice% ChgMarket capCompare
CANFCan-Fite Biopharma Ltd ADR1.44-2.34%$4.35Mvs PCSA
PULMPulmatrix Inc.1.27-10.56%$4.64Mvs PCSA
SCNXScienture Holdings Inc.2.28-6.45%$4.07Mvs PCSA
BLRXBioLineRx Ltd. ADR0.9639-8.20%$4.80Mvs PCSA
LTRNLantern Pharma Inc.0.245-13.73%$3.89Mvs PCSA
ALZNAlzamend Neuro Inc.0.7758-23.94%$3.74Mvs PCSA
SILOSilo Pharma Inc.1.71-9.04%$3.69Mvs PCSA
BGMSBio Green Med Solution Inc.0.553-9.48%$3.66Mvs PCSA

Related